Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques

Expert Opinion on Investigational Drugs

Volumn 13, Issue 8, 2004, Pages 1045-1063

  O'Neill, Alex J ^a   Chopra, Ian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Antibacterial activity; Antibacterial chemotherapy; Antibacterial development; Antibacterial mode of action; Antibacterial resistance; Antibacterial selective toxicity; Antibiotic

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; LINEZOLID; NISIN; NITROFURANTOIN; NORFLOXACIN; NOVOBIOCIN; PENICILLIN DERIVATIVE; PENICILLIN G; POLYMYXIN; PROTEGRIN; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFAMETHOXAZOLE; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIOLYSIS; BACTERIOSTASIS; CLINICAL STUDY; CROSS RESISTANCE; CULTURE MEDIUM; CYTOTOXICITY; DNA REPLICATION; DRUG BINDING; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; ERADICATION THERAPY; ESCHERICHIA COLI; GENE EXPRESSION; GENOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PATHOGENESIS; POSTANTIBIOTIC EFFECT; REVIEW; STAPHYLOCOCCUS AUREUS; TOXICITY TESTING;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICROBIOLOGICAL TECHNIQUES; MOLECULAR BIOLOGY;

EID: 4344593930     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.8.1045     Document Type: Review

References (135)

1. LEVY SB: The Antibiotic Paradox: How Miracle Drugs are Destroying the Miracle. Plenum Press, New York, USA (1992).
2. JOHNSTON N: Seeking superbug-busters. Mod. Drug Discov. (2002) 5:34-36.
3. PROJAN SJ: Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. (2003) 6:427-430.
4. PROJAN SJ: New (and not so new) antibacterial targets - from where and when will the novel drugs come? Curr Opin. Pharmacol. (2002) 2:513-522.
5. CHOPRA I, HESSE L, O'NEILL, AJ: Discovery and development of new antibacterial drugs. In: Trend in Drug Research III: proceedings of the 13th Noordwijkerhout-camerino symposium (Vol. 32). Van der Goot H (Ed.) Elsevier Press, Amsterdam, Holland (2002):213-225.
6. PROJAN SJ, YOUNGMAN PJ: Antimicrobials: new solutions badly needed. Curr. Opin. Microbiol. (2002) 5:463-465.
7. CHOPRA I, HESSE L, O'NEILL AJ: Exploiting current understanding of antibiotic action for discovery of new drugs. J. Appl. Microbiol. (2002) 92:4S-15S.
8. FRANCO CMM, COUTINHO LEL: Detection of novel secondary metabolites. Crit. Rev. Biotechnol. (1991) 11:193-276.
9. DOUGHERTY TJ, PROJAN SJ: Microbial Genomics and Drug Discovery. Marcel Dekker, New York, USA (2003).
10. CHAN PF, MACARRON R, PAYNE DJ, ZALACAIN M, HOLMES DJ: Novel antibacterials: a genomics approach to drug discovery. Curr. Drug Targets Infect. Disord. (2002) 2:291-308.
11. SILVER L, BOSTIAN K. Screening of natural products for antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. (1990) 9:455-461.
12. GOOTZ TD: Discovery and development of new antimicrobial agents. Clin. Microbiol. Rev. (1990) 3:13-31.
13. BILLSTEIN SA: How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimicrob. Agents Chemother. (1994) 38:2679-2682.
14. BEAM TR, GILBERT DN, KUNIN CM: General guidelines for the clinical evaluation of anti-infective drug products. Clin. Infect. Dis. (1992) 15:S5-S32.
15. TUNKEL AR, SCHELD WM: Applications of therapy in animal models to bacterial infection in human disease. Infect. Dis. Clin. North Am. (1989) 3:441-459.
16. . FOOD AND DRUG ADMINISTRATION: Guideline and Format of the Microbiology Section of an Application (Docket No. 85D-0245), US Department of Health and Human Services (1990).
17. Antibiotics in Laboratory Medicine. V Lorian (Ed.), Williams & Wilkins, Baltimore, USA (1996).
18. O'NEILL AJ, OLIVA B, STOREY C et al.: RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. (2000) 44:3163-3166.
19. OLIVA B, MILLER K, CAGGIANO N et al.: Antimicrobial properties and mechanisms of action of novel quinoline-indole agents possessing potent anti-staphylococcal activity. Antimicrob. Agents Chemother. (2003) 47:458-466.
20. EVANS SM, CASARTELLI A, HERREROS E et al: Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. Toxicol. Vitro (2001) 15:579-584.
21. GE Y, DIFUNTORUM S, TOUAMI S et al.: In vitro antimicrobial activity of GSQ1530, a new heteroaromatic polycyclic compound. Antimicrob. Agents Chemother. (2002) 46:3168-3174.
22. PAYNE DJ, MILLER WH, BERRY V et al: Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. (2002) 46:3118-3124.
23. IANDOLO JJ, WORRELL V, GROICHER KH et al: Comparative analysis of the genomes of the temperate bacteriophages phi 11, phi 12 and phi 13 of Staphylococcus aureus 8325. Gene (2002) 289:109-118.
24. FAIRWEATHER N, KENNEDY S, FOSTER TJ, KEHOE M, DOUGAN G: Expression of a cloned Staphylococcus aureus alpha-hemolysin determinant in Bacillus subtilis and Staphylococcus aureus. Infect. Immun. (1983) 41:1112-1117.
25. NIKAIDO H: Multiple antibiotic resistance and efflux. Curr. Opin. Microbiol. (1998) 1:516-523.
26. SULAVIK MC, HOUSEWEART C, CRAMER C et al: Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob. Agents Chemother. (2001) 45:1126-1136.
27. SUKUPOLVI S, VAARA M: Salmonella typhimurium and Escherichia coli mutants with increased outer membrane permeability to hydrophobic compounds. Biochim. Biophys. Acta (1989) 988:377-387.
28. AUSTIN EA, GRAVES JF, HITE LA, PARKER CT, SCHNAITMAN CA: Genetic analysis of lipopolysaccharide core biosynthesis by Escherichia coli K-12: insertion mutagenesis of the rfa locus. J. Bacteriol. (1990) 172:5312-5325.
29. CLARK D: Novel antibiotic hypersensitive mutants of Escherichia coli: Genetic mapping and chemical characterization. FEMS Microbiol. Lett. (1984) 21:189-195.
30. HEISLER LM, SUZUKI H, LANDICK R, GROSS CA: Four contiguous amino acids define the target for streptolydigin resistance in the Beta subunit of Escherichia coli RNA Polymerase. J. Biol. Chem. (1993) 268:25369-25375.
31. LING L, DAVEY ME, SCHUMACHER T et al.: Novel permeable strains of E. coli with improved properties for screening and mechanism of action studies. 43rd Interscience Conference of Antimicrobial Agents & Chemotherapy (2003) (Abstract 1467).
32. KOETH LM, KING A, KNIGHT H et al.: Comparison of cation-adjusted Mueller-Hinton broth with Iso-Sensitest broth for the NCCLS broth microdilution method. J. Antimicrob. Chemother. (2000) 46:369-376.
33. ANDREWS JM: Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother. (2001) 48:5-16.
34. WHEAT PF: History and development of antimicrobial susceptibility testing methodology. J. Antimicrob. Chemother. (2001) 48(Suppl. 1): 14.
35. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (4th Edn). Approved standard M7-A4 National Committee for Clinical Laboratory Standards, Villanova, PA, USA (1997).
36. O'NEILL AJ, BOSTOCK J, MOITA A, CHOPRA I: Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid. J. Antimicrob. Chemother. (2003) 50:839-848.
37. SLATER K: Cytotoxicity tests for high-throughput drug discovery. Curr Opin. Biotechnol. (2001) 12:70-74.
38. BUGELSKI PJ, ATIF U, MOLTON S et al.: A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology. Pharm. Res. (2000) 17:1265-1272.
39. DUNMAN PM, PROJAN SJ: Expression profiling uses in antibacterial chemotherapy development. In: Microbial Genomics and Drug Discovery TJ Dougherty, SJ Projan (Eds), Marcel Dekker, New York, USA (2003).
40. CROWTHER DJ: Applications of microarrays in the pharmaceutical industry. Curr. Opin. Pharmacol. (2002) 2:551-554.
41. GOLLAPUDI BB, KRISHNA G: Practical aspects of mutagenicity testing strategy, an industrial perspective. Mutat. Res. (2000) 455:21-28.
42. ASHBY J, TENNANT RW: Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the US NCI/NTP. Mutat. Res. (1988) 204:17-115.
43. ASHBY J, PATON D: The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures. Mutat. Res. (1993) 286:3-74.
44. MORTELMANS K, ZEIGER E: The Ames Salmonella/microsome mutagenicity assay. Mutat. Res. Fundam. Mol. Mech. Mutagen (2000) 455:29-60.
45. GOCKE E: Mechanism of quinolone mutagenicity in bacteria. Mutat. Res. (1991) 248:135-143.
46. POWER EG, PHILLIPS I: Correlation between umuC induction and Salmonella mutagenicity assay for quinolone antimicrobial agents. FEMS Microbial Lett. (1993) 112:251-254.
47. SHIMADA H, ITOH S, HATTORI C, TADA S, MATSUURA Y: Mutagenicity of the new quinolone antibacterial agent levofloxacin. Arzeimittelforschung (1992) 43:378-385.
48. BEABER JW, HOCHHUT B, WALDOR MK: SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature (2004) 427:72-74.
49. PURVES D, HARVEY C, TWEATS D, LUMLEY CE: Genotoxicity testing: current practices and strategies used by the pharmaceutical industry. Mutagenesis (1995) 10:297-312.
50. GARRIOTT ML, PHELPS JB, HOFFMAN WP: A protocol for the in vitro micronucleus test. I. Contributions to the development of a protocol suitable for regulatory submissions from an examination of 16 chemicals with different mechanisms of action and different levels of activity. Mutat. Res. (2002) 517:123-134.
51. KISKINIS E, SUTER W, HARTMANN A: High throughput Comet assay using 96-well plates. Mutagenesis (2002) 17:37-43.
52. SUCHLAND RJ, GEISLER WM, STAMM WE: Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob. Agents Chemother. (2003) 47:636-642.
53. KING A. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J. Antimicrob. Chemother. (2001) 48(Suppl. 1):77-80.
54. MULLIGAN MJ, COBBS CG: Bacteriostatic versus bactericidal activity. Infect. Dis. Clin. North Am. (1989) 3:389-398.
55. SCHOLAR EM, PRATT WB: The Antimicrobial Drugs. Oxford University Press, New York, USA (2000).
56. OLIVA B, O'NEILL AJ, WILSON JM, O'HANLON PJ, CHOPRA I: Antimicrobial properties and mode of action of the pyrrothine holomycin. Antimicrob. Agents Chemother. (2001) 45:532-539.
57. HILLIARD JJ, GOLDSCHMIDT RM, LICATA L, BAUM EZ, BUSH K: Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems. Antimicrob. Agents Chermother. (1999) 43:1693-1699.
58. SHEN AY, CHEN CP, ROFFLER S: A chelating agent possessing cytotoxicity and antimicrobial activity: 7-morpholinomethyl-8-hydroxyquinoline. Life Sci. (1999) 64:813-825.
59. RASMUSSEN B, NOLLER HF, DAUBRESSE G et al.: Molecular basis of tetracycline action: identification of analogs whose primary target is not the bacterial ribosome. Antimicrob. Agents Chemother. (1991) 35:2306-2311.
60. RODIONOV DG, ISHIGURO EE: Direct correlation between overproduction of guanosine 3′,5′-bispyrophosphate (ppGpp) and penicillin tolerance in Escherichia coli. J. Bacteriol. (1995) 177:4224-4229.
61. TUOMANEN E, TOMASZ A. Induction of autolysis in nongrowing Escherichia coli. J. Bacteriol. (1986) 167:1077-1080.
62. CARSON CF, MEE BJ, RILEY TV. Mechanism of action of Melaleuca alternifolia (tea tree) oil on Staphylococcus aureus determined by time-kill, lysis, leakage, and salt tolerance assays and electron microscopy. Antimicrob. Agents Chemother. (2002) 46:1914-1920.
63. JOHNSTON MD, HANLON GW, DENYER SP, LAMBERT RJ: Membrane damage to bacteria caused by single and combined biocides. J. Appl. Microbiol. (2003) 94:1015-1023.
64. OLIVA B, O'NEILL AJ, MILLER K, STUBBINGS W, CHOPRA I: Antistaphylococcal activity and mode of action of clofazimine. J. Antimicrob. Chemother. (2004) 53:435-440.
65. PORTER EA, WEISBLUM B, GELLMAN SH: Mimicry of host-defense peptides by unnatural oligomers: antimicrobial beta-peptides. J. Am. Chem. Soc. (2002) 124:7324-7330.
66. DIXON RA, CHOPRA I: Polymyxin B and polymyxin B nonapeptide alter cytoplasmic membrane permeability in Escherichia coli. J. Antimicrob. Chemother. (1986) 18:557-563.
67. LING LL, LIANG X, PUYANG X, ARVANITES A, OPPERMAN T: Rapid elimination of compounds acting through non-specific membrane perturbation mechanisms. 43rd Interscience Conference of Antimicrobial Agents, and Chemotherapy Chicago, USA (2003) (Abstract 1469).
68. STUBBINGS WJ, BOSTOCK JM, INGHAM E, CHOPRA I: Assessment of a microplate method for determining the post-antibiotic effect in Staphylococcus aureus and Escherichia coli. J. Antimicrob. Chemother. (2004) 54:139-143.
69. ODENHOLT I: Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int. J. Antimicrob. Agents (2001) 17:1-8.
70. O'GRADY F. LAMBERT HP, FINCH RG, GREENWOOD D: Antibiotic and Chemotherapy Churchill Livingstone, Edinburgh, Scotland (1997).
71. GEORGE RH: The influence of protein binding on the antistaphylococcal activity of antibiotics. J. Antimicrob. Chemother. (1986) 17:539-540.
72. ROYCHOUDHURY S, BRILL JL, LU WP et al.: Development of a screening assay to measure the loss of antibacterial activity in the presence of proteins: its use in optimizing compound structure. J. Biomol. Screen (2003) 8:555-558.
73. VERBIST L: The antimicrobial activity of fusidic acid. J. Antimicrob. Chemother. (1990) 25:1-5.
74. McNAMARA PJ, TRUEB V, STOECKEL K.: Protein binding of ceftriaxone in extravascular fluids. J. Pharm. Sci. (1988) 77:401-404.
75. DECROIX MO, ZINI R, CHAUMEIL JC, TILLEMENT JP: Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs. Biochem. Pharmacol. (1988) 37:2807-2814.
76. BERNAREGGI A, BORGONOVI M, DEL FAVERO A, ROSINA R, GAVANAGHI L: Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers. Eur. J. Drug Metab. Pharmacokinet. (1991) (Spec. No. 3):256-260.
77. CERI H, OLSON ME, STREMICK C et al.: The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbial. (1999) 37:1771-1776.
78. GRAY CP, KECK W. Genomic strategies in antibacterial drug discovery. In: Microbial Genomics and Drug Discovery TJ Dougherty, SJ Projan (Eds), Marcel Dekker, New York, USA (2003).
79. STRUTHERS JK: The use of a continuous culture system to study the antimicrobial susceptibility of bacteria in biofilm. In: Antibiotic Resistance Methods and Protocols. SH Gillespie (Ed.), Humana, Totowa, USA (2000).
80. HODGSON AE, NELSON SM, BROWN MR, GILBERT P: A simple in vitro model for growth control of bacterial biofilms. J. Appl. Bacteriol. (1995) 79:87-93.
81. BUDHANI RK, STRUTHERS JK: The use of Sorbarod biofilms to study the antimicrobial susceptibility of a strain of Streptococcus pneumoniae. J. Antimicrob. Chemother. (1997) 40:601-602.
82. TUCKMAN M, PETERSEN PJ, PROJAN SJ: Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb. Drug Resist. (2000) 6:277-282.
83. BARLOW M, HALL BG: Experimental prediction of the evolution of cefepime resistance from the CMY-2 AmpC β-lactamase. Genetics (2003) 164:23-29.
84. LURIA SA, DELBRUCK M: Mutations of bacteria from virus sensitivity to virus resistance. Genetics (1943) 28:491-511.
85. O'NEILL AJ, COVE JH, CHOPRA I: Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylacoccus aureus. J. Antimicrob. Chemother. (2001) 47:647-650.
86. MOBASHERY S, AZUCENA EF: Bacterial antibiotic resistance. In: Nature Encyclopedia of Life Sciences. Nature Publishing Group, London (1999)
87. MILLER K, O'NEILL AJ, CHOPRA I: Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes. J. Antimicrob. Chemother. (2002) 49:925-934.
88. SCHMID MB: Microbial genomics - new targets, new drugs. Expert Opin. Ther. Targets (2001) 5:465-475.
89. INCE D, ZHANG X, SILVER LC, HOOPER DC: Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. (2003) 47:274-282.
90. O'NEILL AJ, CHOPRA I: Use of mutator strains for characterization of novel antimicrobial agents. Antimicrob. Agents Chemother. (2001) 45:1599-1600.
91. CHOPRA I, O'NEILL AJ, MILLER K: The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updat. (2003) 6:137-145.
92. ZHAO XL, DRLICA K: Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. (2001) 33:S147-S156.
93. ANDERSSON DI, LEVIN BR. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. (1999) 2:489-493.
94. LENSKI RE: The cost of antibiotic resistance - from the perspective of a bacterium. Ciba Found. Symp. (1997) 207:131-140.
95. HURDLE JG, O'NEILL AJ, INGHAM E, FISHWICK C, CHOPRA I: Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modelling techniques. Antimicrob. Agents Chemother. (2004) (In press).
96. NILSSON AI, BERG OG, ASPEVALL O, KAHLMETER G, ANDERSSON DI: Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. (2003) 47:2850-2858.
97. BANDOW JE, BROTZ H, LEICHERT LIO, LABISCHINSKI H, HECKER M: Proteomic approach to understanding antibiotic action. Antimicrob. Agents Chemother. (2003) 47:948-955.
98. DOUGHERTY TJ: In: Microbial Genomics and Drug Discovery TJ Dougherty, SJ Projan (Eds), Marcel Dekker, New York, USA (2003).
99. OLIVA B, MAIESE WM, GREENSTEIN M, BORDERS DB, CHOPRA I: Mode of action of the cyclic depsipeptide antibiotic LL-AO341 β-1 and partial characterization of a Staphylococcus aureus mutant resistant to the antibiotic. J. Antimicrob. Chemother. (1993) 32:817-830.
100. BANERJEE A, DUBNAU E, QUEMARD A et al.: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1994) 263:227-230.
101. DELGADO MA, RINTOUL MR, FARIAS RN, SALOMON RA: Escherichia coli RNA polymerase is the target of the cyclopeptide antibiotic microcin J25. J. Bacteriol. (2001) 183:4543-4550.
102. SIVASUBRAMANIAN N, JAYARAMAN R: Mapping of two transcription mutations (tlnI and tlnII) conferring thiolutin resistance, adjacent to dnaZ and rho in Escherichia coli. Mol. Gen. Genet. (1980) 180:609-615.
103. LUCHANSKY JB, PATTEE PA. Isolation of transposon Tn551 insertions near chromosomal markers of interest in Staphylococcus aureus. J. Bacteriol. (1984) 159:894-899.
104. BELANGER AE, LAI A, BRACKMAN MA, LEBLANC DJ: PCR-based ordered genomic libraries: A new approach to drug target identification for Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2002) 46:2507-2512.
105. UTAIDA S, DUNMAN PM, MACAPAGAL D et al.: Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology (2003) 149:2719-2732.
106. PHADTARE S, KATO I, INOUYE M: DNA microarray analysis of the expression profile of Escherichia coli in response to treatment with 4,5-dihydroxy-2-cyclopenten-1-one. J. Bacteriol. (2002) 184:6725-6729.
107. SHAW KJ, MILLER N, LIU X et al.: Comparison of the changes in global gene expression of Escherichia coli induced by four bactericidal agents. J Mol. Microbiol. Biotechnol. (2003) 5:105-122.
108. EVERS S, DI PADOVA K, MEYER M et al.: Mechanism-related changes in the gene transcription and protein synthesis patterns of Haemophilus influenzae after treatment with transcriptional and translational inhibitors. Proteomics (2001) 1:522-544.
109. SINGH VK, JAYASWAL RK, WILKINSON BJ: Cell wall-active antibiotic induced proteins of Staphylococcus aureus identified using a proteomic approach. FEMS Microbiol. Lett. (2001) 199:79-84.
110. SABINA J, DOVER N, TEMPLETON LJ et al.: Interfering with different steps of protein synthesis explored by transcriptional profiling of Escherichia coli K-12. J. Bacteriol. (2003) 185:6158-6170.
111. GMUENDER H, KURATLI K, DI PADOVA K et al.: Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. Genome Res. (2001) 11:28-42.
112. CHATTERJEE PK, STERNBERG NL: A general genetic approach in Escherichia coli for determining the mechanism(s) of action of tumoricidal agents: application to DMP 840, a tumoricidal agent. Proc. Natl. Acad. Sci. USA (1995) 92:8950-8954.
113. HUANG J, HE J, SHEN W et al: A novel approach for studying antibiotic mode of action and resistance using a Staphylococcus aureus ORF expression library. 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy Chicago, USA (2003) (Abstract 1468).
114. APFEL CM, LOCHER H, EVERS S et al: Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. (2001) 45:1058-1064.
115. DEVITO JA, MILLS JA, LIU VG et al.: An array of target-specific screening strains for antibacterial discovery. Nat. Biotechnol. (2002) 20:478-483.
116. FAN F, LUNSFORD RD, SYLVESTER D et al.: Regulated ectopic expression and allelic-replacement mutagenesis as a method for gene essentiality testing in Staphylococcus aureus. Plasmid (2001) 46:71-75.
117. ZHANG L, FAN F, PALMER LM et al: Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene (2000) 255:297-305.
118. fcsK) suitable for gene essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae. J. Bacteriol. (2003) 185:2051-2058.
119. YIN D, FOX B, LONETTO ML et al.: Identification of antimicrobial targets using a comprehensive genomic approach. Pharmacogenomics (2004) 5:101-113.
120. FORSYTH RA, HASELBECK RJ, OHLSEN KL et al.: A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. (2002) 43:1387-1400.
121. GOOD L: Diverse antisense mechanisms and applications. Cell. Mol. Life Sci. (2003) 60:823-824.
122. GOOD L, NIELSEN PE: Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat Biotechnol. (1998) 16:355-358.
123. TAO J, WENDLER P, CONNELLY G et al.: Drug target validation: lethal infection blocked by inducible peptide. Proc. Natl. Acad Sci. USA (2000) 97:783-786.
124. STUBBINGS W, INGHAM E, CHOPRA I: Deletion of the multiple drug efflux pump AcrAB in Escherichia coli prolongs the postantibiotic effect. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (2002).
125. TENOVER FC: Development and spread of bacterial resistance to antimicrobial agents: an overview. Clin. Infect. Dis. (2001) 33(Suppl. 3):S108-S115.
126. CLARK NM, HERSHBERGER E, ZERVOSC MJ, LYNCH JP 3rd: Antimicrobial resistance among Gram-positive organisms in the intensive care unit. Curr. Opin. Crit. Care (2003) 9:403-412.
127. CLARK NM, PATTERSON J, LYNCH JP 3rd. Antimicrobial resistance among Gram-negative organisms in the intensive care unit. Curr. Opin. Crit. Care (2003) 9:413-423.
128. PUBLIC HEALTH LABORATORY SERVICE: Antimicrobial resistance in 2000: England & Wales: Public Health Laboratory Service, London (2002).
129. DRLICA K: Mechanism of fluoroquinolone action. Curr. Opin. Microbiol. (1999) 2:504-508.
130. BIANCHI AA, BANEYX F: Stress responses as a tool to detect and characterize the mode of action of antibacterial agents. Appl. Environ. Microbiol. (1999) 65:5023-5027.
131. SHAPIRO E, BANEYX F: Stress-based identification and classification of antibacterial agents: second-generation Escherichia coli reporter strains and optimization of detection. Antimicrob. Agents Chemother. (2002) 46:2490-2497.
132. OH JT, CAJAL Y, SKOWRONSKA EM et al.: Cationic peptide antimicrobials induce selective transcription of micF and osmY in Escherichia coli. Biochim. Biophys. Acta (2000) 1463:43-54.
133. FISCHER HP, BRUNNER NA, WIELAND B et al: Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery. Genome Res. (2004) 14:90-98.
134. SUN D, COHEN S, MANI N, MURPHY C, ROTHSTEIN DM: A pathway-specific cell based screening system to detect bacterial cell wall inhibitors. J. Antibiot. (Tokyo) (2002) 55:279-287.
135. CHOPRA I: Antibiotics. In: Nature Encyclopedia of Life Sciences Nature Publishing Group, London (June 2001). http://www.els.net/